OraSure Technologies, Inc. (OSUR) said Wednesday that the U.S. Food and Drug Administration Blood Products Advisory Committee will consider the company's application for the approval of its OraQuick Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter market at a meeting scheduled for May 15.
The company said it will be presenting the findings from the final phase of clinical testing, which involved the use of the OraQuick In-Home HIV Test, an OTC investigational use version of the OraQuick ADVANCE Rapid HIV-1/2 test, by individuals in an unobserved setting.
About 5,800 subjects were enrolled and tested in this phase across 20 sites nationwide, resulting in the identification of more than 100 previously undiagnosed individuals with HIV, the company said.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.